Link Pharmachem Q4 FY26 Results: PAT Rs 0.55 Cr

Link Pharmachem Q4 FY26 results were declared on May 21, 2026. The company reported PAT of Rs 0.55 crore for the quarter ended March 31, 2026, up 14.6% YoY compared to Rs 0.48 crore in Q4 FY25. Revenue from operations stood at Rs 6.59 crore, up 2.2% YoY. Results are on a Standalone basis. Link Pharmachem is a Pharmaceutical Chemicals company listed on Indian stock exchanges.

Click Here – Get Free Investment Predictions

Link Pharmachem Q4 FY26 Financial Highlights

Metric	Q4 FY26 (Rs Cr)	Q4 FY25 (Rs Cr)	YoY Change
Revenue	Rs 6.59 crore	Rs 6.45 crore	+2.2%
Net Profit	0.55	0.48	+14.6%
Basis	Standalone

Note: Q4 FY26 standalone revenue Rs 6.59 crore (+2.21% YoY). Pharmaceutical and specialty chemicals manufacturer. Verify from BSE/NSE audited filings before investment decisions.

Link Pharmachem Q4 FY26 Performance Analysis

The Link Pharmachem Q4 FY26 results reflect the company’s operational performance during the January to March 2026 quarter. The company delivered results in line with its sector trends during the quarter. Link Pharmachem operates in the Pharmaceutical Chemicals sector, benefiting from India’s GDP growth above 6.5% in FY26 and sustained domestic demand conditions.

Revenue of Rs 6.59 crore was up 2.2% YoY. Steady revenue momentum reflects consistent business conditions.

Screen the best stocks on the Univest Screener.

Key Factors Driving Link Pharmachem Q4 FY26 Results

Revenue and Operational Performance

Revenue of Rs 6.59 crore in Link Pharmachem Q4 FY26 was up 2.2% YoY. Revenue performance reflects stable demand conditions. The January to March period is the year-end quarter for Indian companies, characterised by strong execution cycles, project completions, and fiscal year-end activity.

Profitability Trends

The Link Pharmachem Q4 FY26 PAT of Rs 0.55 crore up 14.6% YoY. Stable profitability reflects consistent operational delivery.

Sector and Macro Context

India’s macro environment in Q4 FY26 was supportive, with GDP growth above 6.5%, government capital expenditure of Rs 11.21 lakh crore budgeted for FY27, and resilient domestic consumption. The Pharmaceutical Chemicals sector saw broadly constructive demand conditions. For Link Pharmachem, these macro tailwinds provided a supportive backdrop entering FY27.

FY27 Outlook

Following the firm results, management commentary on FY27 revenue guidance, margin improvement trajectory, and capital allocation priorities will be the key investor watchpoints. The Pharmaceutical Chemicals sector continues to benefit from India’s structural growth drivers. Delivering consistent growth and margin expansion remains the strategic priority.

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.

Frequently Asked Questions on the company

Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Verify all figures from BSE/NSE filings. Consult a SEBI-registered financial advisor.